We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Raises Impurity Threshold to Address Losartan Shortage
FDA Raises Impurity Threshold to Address Losartan Shortage
The FDA said it will allow drugmakers to sell losartan with higher levels of a potentially cancerous impurity over the next six months to prevent a shortage of the blood pressure drug.